UA70351C2 - Method for producing lyophilisates with improved dmethod for producing lyophilisates with improved dissolution rate and particle-free reconstitution (issolution rate and particle-free reconstitution (variants) variants) - Google Patents
Method for producing lyophilisates with improved dmethod for producing lyophilisates with improved dissolution rate and particle-free reconstitution (issolution rate and particle-free reconstitution (variants) variants) Download PDFInfo
- Publication number
- UA70351C2 UA70351C2 UA2001085974A UA2001085974A UA70351C2 UA 70351 C2 UA70351 C2 UA 70351C2 UA 2001085974 A UA2001085974 A UA 2001085974A UA 2001085974 A UA2001085974 A UA 2001085974A UA 70351 C2 UA70351 C2 UA 70351C2
- Authority
- UA
- Ukraine
- Prior art keywords
- lyophilisates
- particle
- variants
- producing
- improved
- Prior art date
Links
- 238000004090 dissolution Methods 0.000 title abstract description 4
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000000859 sublimation Methods 0.000 description 3
- 230000008022 sublimation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- -1 alkylene glycols Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- IWXNYAIICFKCTM-UHFFFAOYSA-N cariporide Chemical compound CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O IWXNYAIICFKCTM-UHFFFAOYSA-N 0.000 description 1
- 229950008393 cariporide Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PFSNEEPXSAWFHI-UHFFFAOYSA-N n-(diaminomethylidene)-2-methyl-5-methylsulfonyl-4-pyrrol-1-ylbenzamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=C(C(=O)N=C(N)N)C(C)=CC(N2C=CC=C2)=C1S(C)(=O)=O PFSNEEPXSAWFHI-UHFFFAOYSA-N 0.000 description 1
- FNDLQABGYJQJPH-UHFFFAOYSA-N n-(diaminomethylidene)-3-methylsulfonyl-4-propan-2-ylbenzamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)C1=CC=C(C(=O)N=C(N)N)C=C1S(C)(=O)=O FNDLQABGYJQJPH-UHFFFAOYSA-N 0.000 description 1
- AJDQRQQNNLZLPM-UHFFFAOYSA-N n-(diaminomethylidene)benzamide Chemical compound NC(N)=NC(=O)C1=CC=CC=C1 AJDQRQQNNLZLPM-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Waveguide Aerials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19903275A DE19903275A1 (de) | 1999-01-28 | 1999-01-28 | Lyophilisate mit verbesserter Rekonstituierbarkeit |
| PCT/EP2000/000569 WO2000044354A1 (de) | 1999-01-28 | 2000-01-26 | Lyophilisate mit verbesserter rekonstituierbarkeit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA70351C2 true UA70351C2 (en) | 2004-10-15 |
Family
ID=7895601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001085974A UA70351C2 (en) | 1999-01-28 | 2000-01-26 | Method for producing lyophilisates with improved dmethod for producing lyophilisates with improved dissolution rate and particle-free reconstitution (issolution rate and particle-free reconstitution (variants) variants) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6770678B1 (hu) |
| EP (1) | EP1146863B1 (hu) |
| JP (2) | JP4562288B2 (hu) |
| KR (1) | KR20010108136A (hu) |
| AT (1) | ATE266387T1 (hu) |
| AU (1) | AU757781B2 (hu) |
| BR (1) | BRPI0007714B8 (hu) |
| CA (1) | CA2361237C (hu) |
| CZ (1) | CZ20012693A3 (hu) |
| DE (2) | DE19903275A1 (hu) |
| DK (1) | DK1146863T3 (hu) |
| ES (1) | ES2220404T3 (hu) |
| HU (1) | HU226585B1 (hu) |
| NO (1) | NO331321B1 (hu) |
| PL (1) | PL351140A1 (hu) |
| PT (1) | PT1146863E (hu) |
| RU (1) | RU2225709C2 (hu) |
| SK (1) | SK10542001A3 (hu) |
| UA (1) | UA70351C2 (hu) |
| WO (1) | WO2000044354A1 (hu) |
| ZA (1) | ZA200107081B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2471144C (en) | 2002-01-09 | 2011-06-07 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate |
| DE102004045825A1 (de) * | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Lyophilisat enthaltend N-Diaminomethylen-2-methyl-4,5-di-(methylsulfonyl)-benzamid |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| ES2804574T3 (es) | 2008-05-09 | 2021-02-08 | Merck Patent Gmbh | Composición farmacéutica para tratar enfermedades asociadas con la resistencia a la insulina y la disfunción de células beta |
| EP2346826A2 (en) * | 2008-06-09 | 2011-07-27 | AWD.pharma GmbH & Co.KG | Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine |
| US7795263B2 (en) * | 2008-07-08 | 2010-09-14 | Wildlife Laboratories, Inc. | Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals |
| TW201920174A (zh) * | 2017-09-27 | 2019-06-01 | 瑞士商羅氏大藥廠股份有限公司 | 二氮雜雙環辛烷衍生物之醫藥形式及其製法 |
| US11679083B2 (en) | 2017-12-28 | 2023-06-20 | Fujifilm Toyama Chemical Co., Ltd. | Method for producing freeze-dried formulation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4002748A (en) * | 1976-01-19 | 1977-01-11 | Eli Lilly And Company | Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration |
| JPH07114946B2 (ja) * | 1988-10-24 | 1995-12-13 | 株式会社奈良機械製作所 | 難溶性物質の処理方法 |
| US5066647A (en) * | 1989-04-20 | 1991-11-19 | Erbamont, Inc. | Cyclophosphamide - alanine lyophilizates |
| DE59305042D1 (de) * | 1992-09-22 | 1997-02-20 | Hoechst Ag | Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika |
| JP2747967B2 (ja) * | 1993-07-23 | 1998-05-06 | 雪印乳業株式会社 | シアル酸粉末 |
| ZA949182B (en) * | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
| DE4430861A1 (de) * | 1994-08-31 | 1996-03-07 | Merck Patent Gmbh | Heterocyclyl-benzoylguanidine |
| DE19529612A1 (de) * | 1995-08-11 | 1997-02-13 | Merck Patent Gmbh | Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate |
| JPH09183729A (ja) * | 1995-12-29 | 1997-07-15 | Meiji Milk Prod Co Ltd | 凍結乾燥ウラシルを含有する抗腫瘍医薬組成物 |
-
1999
- 1999-01-28 DE DE19903275A patent/DE19903275A1/de not_active Withdrawn
-
2000
- 2000-01-26 UA UA2001085974A patent/UA70351C2/uk unknown
- 2000-01-26 AT AT00906226T patent/ATE266387T1/de active
- 2000-01-26 DE DE50006404T patent/DE50006404D1/de not_active Expired - Lifetime
- 2000-01-26 PT PT00906226T patent/PT1146863E/pt unknown
- 2000-01-26 CA CA002361237A patent/CA2361237C/en not_active Expired - Lifetime
- 2000-01-26 SK SK1054-2001A patent/SK10542001A3/sk unknown
- 2000-01-26 WO PCT/EP2000/000569 patent/WO2000044354A1/de active IP Right Grant
- 2000-01-26 ES ES00906226T patent/ES2220404T3/es not_active Expired - Lifetime
- 2000-01-26 JP JP2000595658A patent/JP4562288B2/ja not_active Expired - Lifetime
- 2000-01-26 AU AU27986/00A patent/AU757781B2/en not_active Expired
- 2000-01-26 BR BRPI0007714A patent/BRPI0007714B8/pt not_active IP Right Cessation
- 2000-01-26 RU RU2001122707/15A patent/RU2225709C2/ru active
- 2000-01-26 EP EP00906226A patent/EP1146863B1/de not_active Expired - Lifetime
- 2000-01-26 CZ CZ20012693A patent/CZ20012693A3/cs unknown
- 2000-01-26 US US09/889,930 patent/US6770678B1/en not_active Expired - Lifetime
- 2000-01-26 KR KR1020017009423A patent/KR20010108136A/ko not_active Application Discontinuation
- 2000-01-26 DK DK00906226T patent/DK1146863T3/da active
- 2000-01-26 PL PL00351140A patent/PL351140A1/xx unknown
- 2000-01-26 HU HU0105493A patent/HU226585B1/hu not_active IP Right Cessation
-
2001
- 2001-07-27 NO NO20013703A patent/NO331321B1/no not_active IP Right Cessation
- 2001-08-27 ZA ZA200107081A patent/ZA200107081B/xx unknown
-
2010
- 2010-06-02 JP JP2010126408A patent/JP2010264249A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR0007714B1 (pt) | 2014-09-30 |
| HU226585B1 (en) | 2009-04-28 |
| HUP0105493A2 (en) | 2002-06-29 |
| NO20013703D0 (no) | 2001-07-27 |
| EP1146863B1 (de) | 2004-05-12 |
| HUP0105493A3 (en) | 2006-07-28 |
| RU2225709C2 (ru) | 2004-03-20 |
| ZA200107081B (en) | 2003-02-26 |
| NO331321B1 (no) | 2011-11-21 |
| CA2361237A1 (en) | 2000-08-03 |
| BRPI0007714B8 (pt) | 2021-05-25 |
| ATE266387T1 (de) | 2004-05-15 |
| PL351140A1 (en) | 2003-03-24 |
| AU757781B2 (en) | 2003-03-06 |
| US6770678B1 (en) | 2004-08-03 |
| CA2361237C (en) | 2008-07-15 |
| AU2798600A (en) | 2000-08-18 |
| BR0007714A (pt) | 2001-11-27 |
| WO2000044354A1 (de) | 2000-08-03 |
| DE19903275A1 (de) | 2000-08-03 |
| JP4562288B2 (ja) | 2010-10-13 |
| PT1146863E (pt) | 2004-10-29 |
| JP2002535089A (ja) | 2002-10-22 |
| DE50006404D1 (de) | 2004-06-17 |
| JP2010264249A (ja) | 2010-11-25 |
| CZ20012693A3 (cs) | 2002-01-16 |
| DK1146863T3 (da) | 2004-08-30 |
| ES2220404T3 (es) | 2004-12-16 |
| EP1146863A1 (de) | 2001-10-24 |
| SK10542001A3 (sk) | 2002-01-07 |
| KR20010108136A (ko) | 2001-12-07 |
| NO20013703L (no) | 2001-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9651305B2 (en) | Lyophilization system and method | |
| JP2010264249A (ja) | 改善された再生能を有する凍結乾燥体 | |
| CA2234140C (fr) | Formulation pharmaceutique lyophilisee stable | |
| Izutsu et al. | Physical stability and protein stability of freeze-dried cakes during storage at elevated temperatures | |
| HU221428B (en) | Lyophilized compositions containing ifosfamide and urea and process for production of them | |
| KR102440847B1 (ko) | 고순도의 칸그렐러를 포함하는 약제학적 제제, 및 이들의 제조 및 사용 방법 | |
| BRPI0719096A2 (pt) | Formulação parenteral estavel contendo uminibidor de rsv de uma estrutura de benzodiazepina | |
| EP0782850A1 (en) | Lyophilized preparation providing reversibly thermogelling water-base medicinal composition | |
| JP2023116657A (ja) | 安定な滅菌性且つ結晶性ｏ－アセチルサリチル酸（アスピリン）のバイアル内堆積物 | |
| JP3726255B2 (ja) | 安定な凍結乾燥済みチオテパ組成物 | |
| US4963551A (en) | Stable lyophilized form of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and solutions thereof | |
| JP2002535089A5 (hu) | ||
| SK283137B6 (sk) | Farmaceutické kompozície na liečbu poruchy agregácie krvných doštičiek a spôsob jej prípravy | |
| JP2011137048A (ja) | 新たな用途の薬学的調製物およびその調製物を製造するためのプロセス | |
| US5972912A (en) | Method for lyophilizing ifosfamide | |
| JP2003527207A (ja) | リネゾリド静脈内溶液用容器 | |
| JPS61171421A (ja) | 安定なプロスタグランジンｅ類製剤の製造方法 | |
| RU2080857C1 (ru) | Способ получения инъекционной формы препарата хондроитинсульфата "хондролон" | |
| MXPA01007576A (en) | Lyophilisates with improved reconstitutibility | |
| Chakradhar et al. | Formulation and characterization of cyclophosphamide injections using lyophilization technique | |
| JP3028298B2 (ja) | 経口用トロンビン製剤 | |
| RU94030750A (ru) | Способ получения комбинированной лекарственной формы антибиотиков пенициллинового ряда | |
| JPH02101014A (ja) | １−〔（４´‐ヒドロキシ‐２´‐ブテノキシ）メチル〕‐２‐ニトロイミダゾールの凍結乾燥製剤の製造方法 | |
| GB2271281A (en) | Stabilised cyclophosphamide compositions |